Severe cognitive impairment is linked to a reduced gut microbiome capacity to synthesise immunomodulators, neurotransmitters, and amino acids required for autophagy in residents of long-term aged care

Andrew P. Shoubridge[1,2], Lucy Carpenter[1,2], Erin Flynn[1], Lito E. Papanicolas[1,2,3], Josephine Collins[1], David Gordon[3,4], David J. Lynn[2,5], Craig Whitehead[6,7], Lex E.X. Leong[3], Monica Cations[7,8], David P. De Souza[9], Vinod K. Narayana[9], Jocelyn M. Choo[1,2], Steve L. Wesselingh[1,2,7], Maria Crotty[6,7], Maria C. Inacio[7,10], Kerry Ivey[1,11], Steven L. Taylor[1,2#], Geraint B. Rogers[1,2#*]

[1] Microbiome and Host Health Program, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.

[2] Infection and Immunity, Flinders Health and Medical Research Institute, College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia.

[3] SA Pathology, SA Health, Adelaide, SA, Australia.

[4] Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, SA, Australia.

[5] Computational & Systems Biology Program, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.

[6] Department of Rehabilitation, Aged and Palliative Care, Flinders Medical Centre, Flinders University, Bedford Park, SA, Australia.

[7] Registry of Senior Australians, South Australian Health and Medical Research Institute, Adelaide, SA, Australia.

[8] College of Education, Psychology and Social Work, Flinders University, Bedford Park, SA, Australia

[9] Bio21 Institute and Department of Biochemistry and Molecular Biology, University of

Melbourne, Parkville, VIC, Australia.

[10] Allied Health and Human Performance, University of South Australia, Adelaide, SA,

Australia.

[11] Department of Nutrition, Harvard University T.H. Chan School of Public Health, Boston,

MA, USA.

[#] These authors share senior authorship.

[*] Correspondence:

Professor Geraint B. Rogers

Director, Microbiome & Host Health, South Australian Health and Medical Research

Institute, North Terrace, Adelaide, SA 5001, Australia.

geraint.rogers@sahmri.com

+61 (0)403 558251

Abstract

Ageing-associated cognitive decline affects more than half of those in long-term residential aged care. Emerging evidence suggests that gut microbiome-host interactions influence the effects of modifiable risk factors. We investigated the relationship between gut microbiome characteristics and severity of cognitive impairment (CI) in 159 residents of long-term aged care. Severe CI was associated with a significantly increased abundance of proinflammatory bacterial species, including *Methanobrevibacter smithii* and *Alistipes finegoldii*, and decreased relative abundance of beneficial bacterial clades. Severe CI was associated with increased microbial capacity for methanogenesis, and reduced capacity for synthesis of short-chain fatty acids, neurotransmitters glutamate and gamma-aminobutyric acid, and amino acids required for neuro-protective lysosomal activity. These relationships were independent of age, sex, antibiotic exposure, and diet. Our findings implicate multiple gut microbiome-brain pathways in ageing-associated cognitive decline, including inflammation, neurotransmission, and autophagy, and highlight the potential to predict and prevent cognitive decline through microbiome-targeted strategies.

Main

Progressive loss of cognitive function is a common feature of ageing and is not limited to those with dementia (Albert et al., 1995; Comijs et al., 2004; Harada et al., 2013; Verdi et al., 2018). Contributory pathologies, often occurring in combination, include ischaemic or haemorrhagic infarcts within the brain (characteristic of vascular dementia) (Henon et al., 2001; Ye et al., 2015), the accumulation of amyloid plaques and neurofibrillary tangles (characteristic of Alzheimer's disease) (Bussian et al., 2018; Luo et al., 2020), and the development of abnormal collections of alpha-synuclein protein within diseased brain neurons (characteristic of Lewy body dementia) (Lin et al., 2017; Mattila et al., 2000). While these pathophysiological processes are increasingly well-characterised, the factors that contribute to them and their relationship to external risk exposures remain poorly understood.

In addition to genetic factors (Koistinaho et al., 2004; Lin et al., 2018; Liu et al., 2017; Parcon et al., 2018; Shi et al., 2017; Ulrich et al., 2018), modifiable risk factors associated with dementia have been identified. Modifiable risk factors include exposures (smoking, excessive alcohol consumption, physical inactivity, air pollution, diet); health conditions (hypertension, obesity, depression, diabetes, traumatic brain injury, hearing impairment), and social factors (less education, and low social contact) (Livingston et al., 2020). Together, these modifiable risk factors are estimated to account for 40% of dementia incidence (Livingston et al., 2020). Identifying how such factors influence the pathophysiology of ageing-associated cognitive impairment (CI) is essential to the development of effective prevention and treatment.

The gut microbiome influences neurophysiology, central nervous system, and cognitive function through discrete bidirectional pathways, collectively termed the microbiome-gut-brain axis (Cryan et al., 2019; Rogers et al., 2016; Sharon et al., 2016; Shoubridge et al., 2022).

These pathways include the microbial synthesis of neurotransmitters, such as gamma-

aminobutyric acid (GABA), noradrenaline, dopamine and serotonin (Valles-Colomer et al.,

2019; Yano et al., 2015), the modulation of systemic immunity (Correa-Oliveira et al., 2016;

Dalile et al., 2019), and metabolism of essential amino acids, such as tyramine and tryptophan

(Lai et al., 2021; Marx et al., 2021). They also involve production of immune and metabolically

active metabolites, such as short-chain fatty acids (SCFAs) and 4-ethylphenylsulfate, and

activation of nerve growth factor, glial-derived neurotrophic factor, and brain-derived

neurotrophic factor secretion (Bonfili et al., 2021; Soto et al., 2018). Such microbial traits have

the potential to contribute substantially to the development of neurological diseases, including

Alzheimer's (Kim et al., 2020; Vogt et al., 2017), Huntington's (Bjorkqvist et al., 2008; Du et

al., 2020; Wasser et al., 2020), and Parkinson's diseases (Sampson et al., 2016; Sun et al.,

2018).

Ageing-associated gut microbiome characteristics (Claesson et al., 2011; Meyer et al., 2022)

are linked to progressive frailty and cognitive decline (Komanduri et al., 2021; Manderino et

al., 2017; Meyer et al., 2022; Verdi et al., 2018). External exposures that disrupt the

microbiome, such as antibiotics, can further contribute to altered neurological homeostasis and

poorer cognitive outcomes (Desbonnet et al., 2015; Frohlich et al., 2016; Lynn et al., 2021). In

contrast, dietary interventions that alter the composition of the gut microbiome in a beneficial

manner can result in improvements in cognitive function (Ghosh et al., 2020). Such findings

suggest that the relationship between the gut microbiome and host neurophysiology may

provide a basis to predict and/or prevent the onset and progression of ageing-associated

cognitive decline. Potential causality in these relationships is suggested by studies that have

successfully recapitulated impairment of memory and synaptic plasticity following faecal

microbiota transplant from aged mice to younger mice (D'Amato et al., 2020).

Our aim was to explore whether the severity of CI experienced by residents of long-term aged

care facilities (sometimes referred to as nursing homes, care homes, or residential aged care

facilities) is associated with characteristics of the gut microbiome, and if so, whether such

relationships might provide mechanistic insight into CI pathogenesis.

Results

The study group of 159 participants did not differ from the original GRACE cohort in any of the assessed characteristics (**Supplementary Table 1**). CI was classified as mild in 46 individuals (28.9%) with a median PAS-CIS score of 6.6 (IQR=5.0-8.0), moderate in 58 (36.5%; PAS-CIS median=11.0; IQR=11.0-12.8), and severe in 55 (34.6%; PAS-CIS median=18.0; IQR=17.0-18.8) (**Table 1; Supplementary Fig. 2A**). The median time from assessment of cognitive skills to the subsequent collection of stool samples was 437 days (IQR: 185-741). Participant age, sex ratio, time since cognitive assessment, and use of antibiotics, opioids, and laxatives, did not differ significantly between CI severity categories ($p > 0.05$; **Supplementary Fig. 2B-F**). However, the number of days that an individual had been residing in long-term aged care was significantly higher for those in the severe CI group (median=939 days; IQR=219-854) compared to the mild CI group (median=500 days; IQR=130-627; $p < 0.05$). Proton pump inhibitor usage was significantly lower in the severe CI group ($p < 0.05$). Within the severe CI group, 53/55 (96.4%) had a concurrent diagnosis of dementia, 33/58 (56.9%) of moderate CI had a dementia diagnosis, and 4/46 (8.7%) of those with mild CI.

Gut microbiome characteristics differ by CI severity

A total of 11 bacterial phyla were detected across the 159 stool samples, consisting of 186 genera (586 species). The composition and distribution of taxa was broadly similar with previous studies of aged populations (Claesson et al., 2011; Jackson et al., 2016), with high representation of *Eggerthella lenta, Escherichia coli*, *Faecalibacterium prausnitzii*, and *Clostridium* species (**Fig. 1A**), and genera within the Bacteroidota (formerly Bacteroides) and Bacillota (Firmicutes) phyla (**Fig. 1B**).

Following adjustment for time since cognitive assessment, age, sex, medication use, and diet,

the faecal microbiota composition differed significantly between mild, moderate, and severe

CI (p(perm)=0.0003; R^2=2.21%; **Fig. 1C; Table 2**). This difference was greatest between

severe CI and mild CI (p(perm)=0.0023), and severe CI and moderate CI (p(perm)=0.0003),

and consistent with the unadjusted model (**Table 2**). Repeated analysis using weighted and

unweighted UniFrac dissimilarity did not identify significant intergroup differences, apart from

between mild and moderate CI groups using weighted UniFrac dissimilarity (unadjusted

p(perm)=0.037; **Supplementary Fig. 4**).

Analysis of microbiota diversity identified a positive association between CI severity and taxa

richness (odds ratio (OR): 1.08 [95% confidence interval 1.05, 1.12], q<0.001) and Shannon-

Wiener diversity (OR: 1.043 [1.013, 1.073], q<0.05; **Fig. 1D**). However, there was no

association between CI severity and Pielou's evenness (OR: 0.985 [0.957, 1.014], q>0.05; **Fig.**

1D).

To assess whether specific taxa differed with CI, phylum-level and species-level relative

abundances were assessed. Of the seven phyla present in at least 30% of participants, five

differed significantly with CI (**Fig. 2**). Pseudomonadota (Proteobacteria) (OR: 0.937 [0.909,

0.965], q<0.001) and Bacillota (OR: 0.943 [0.915, 0.971], q<0.001) were lower with increasing

CI severity (**Fig. 2**). In contrast, Euryarchaeota (OR: 1.097 [1.065, 1.131], q<0.001),

Actinomycetota (Actinobacteria) (OR: 1.066 [1.035, 1.099], q<0.001), and Synergistota

(Synergistetes) (OR: 1.043 [1.008, 1.079], q<0.05) were higher with increasing CI severity

(**Fig. 2**).

Bacterial species that were detected in at least 60% of participants, and with a relative

abundance of at least 0.1%, were denoted as "core" taxa (**Supplementary Table 2**). Of the 586

microbial species identified across the entire cohort, 30 were identified as core in mild CI

(**Supplementary Fig. 5A**), 31 in moderate CI (**Supplementary Fig. 5B**), and 29 in severe CI

(**Supplementary Fig. 5C**).

Comparison of species relative abundances identified 50 species that differed significantly with

CI severity (**Fig. 3**). Notably, *Blautia hydrogentrophica* (OR: 1.135 [1.099, 1.173]),

Catabacter hongkongensis (OR: 1.131 [1.096, 1.168]), and *Alistipes finegoldii* (OR: 1.089

[1.058, 1.121]), had the strongest positive association with CI severity (all q<0.001, **Fig. 3**).

Further, *Collinsella aerofaciens* and *Methanobrevibacter smithii* were not only positively

associated with CI severity (q<0.001, **Fig. 3**), they were also core species in severe CI, but not

mild or moderate (**Supplementary Table 2, Supplementary Fig. 5**). In contrast, *Bacteroides*

uniformis (OR: 0.935 [0.908, 0.962]), *Blautia producta* (OR: 0.916 [0.888, 0.945]) and *Blautia*

wexlerae (OR: 0.940 [0.913, 0.968]) were among those with the strongest inverse association

with CI severity (all q<0.001, **Fig. 3**). *Faecalibacterium prausnitzii*, a species previously

associated with health outcomes in ageing (Jackson et al., 2016), was also found to trend lower

in this cohort with increasing CI severity, but this did not achieve statistical significance (OR:

0.986 [0.958, 1.014], q=0.421).

The functional capacity and output of the gut microbiota differs with CI severity

Differences in the functional capacity of the gut microbiota were identified with increasing CI

severity. Four hundred MetaCyc pathways were detected in >30% of participants, of which, 70

were selected based on their potential influence on CI. Pathways inversely associated with CI

severity included PWY-5505, a pathway essential to the production of the primary excitatory

neurotransmitter glutamate (OR: 0.922 [0.895, 0.949], q<0.001), and GLUDEG-I-PWY, a

pathway essential to the production of the primary inhibitory neurotransmitter GABA (OR:

0.962 [0.934, 0.990], q<0.05, **Fig. 4**). Similarly, pathways related to the production of SCFAs,

including acetate (P461-PWY; OR: 0.877 [0.850, 0.904], q<0.001), propionate (P108-PWY;

OR: 0.939 [0.913, 0.966], q<0.001), and butyrate (PWY-5022; OR: 0.935 [0.908, 0.962],

q<0.001) were also lower in relative abundance as CI severity increased. Functional pathways

related to the biosynthesis of amino acids L-arginine (PWY-5154; OR: 0.911 [0.884, 0.938],

q<0.001), L-lysine, L-threonine, and L-methionine (P4-PWY; OR: 0.905 [0.878, 0.932],

q<0.001), were among the most depleted at higher CI severity (**Fig. 4**).

Metabolomic analysis of a randomly selected subgroup of individuals (n=35; n=11-12/group)

confirmed these findings. A total of 165 polar metabolites were detected in stool samples from

these participants, including 33 metabolites classed as amino acids, peptides, and analogues,

50 classed as lipids and lipid-like molecules, 18 classed as carbohydrates, and 64 classed within

other categories (**Supplementary Fig. 6A**), in addition to nine SCFAs (**Supplementary Fig.**

6B). Detectable SCFA metabolites and amino acid polar metabolites decreased with increasing

CI severity (**Supplementary Fig. 7**). Further exploratory analysis across all functional

pathways (n=400) identified 271 statistically significantly altered pathways, with multiple

pathways related to methanogenesis among those of greatest significance and higher relative

abundance (**Supplementary Table 3**). The relative abundances of metagenomic pathways and

the levels of associated metabolites were positively correlated (**Supplementary Fig. 8**).

Discussion

We report significant associations between characteristics of the faecal microbiome and the severity of CI in residents of long-term aged care facilities. Microbiome CI severity-associated traits were identified even after adjustment for age, sex, prior medication exposure, and diet. Individuals with more severe CI exhibited a greater representation of the Actinomycetota phylum and *Methanobrevibacter smithii*, and a lower prevalence of *Bacteroides uniformis*, a reduced capacity for synthesis of SCFAs, neurotransmitters (glutamate and GABA), and amino acids that are essential for autophagy, and an increased capacity for methanogenesis. These findings identify microbial factors potentially influencing ageing-associated cognitive decline, and present opportunities for prediction and treatment of CI.

Changes in intestinal microbiology can influence neuroplastic changes in the brain via a range of mechanisms (Cryan et al., 2019; Rogers et al., 2016; Sharon et al., 2016; Shoubridge et al., 2022). Many of these pathways relate to the production of specific factors by the gut microbiota, including the biosynthesis of immunomodulatory metabolites and neurotransmitters (Correa-Oliveira et al., 2016; Erny et al., 2015), amino acid metabolism (Bellono et al., 2017; Ye et al., 2021), and the release of pro-inflammatory cytokines (Arentsen et al., 2017; Erny et al., 2015; Kim et al., 2013).

We assessed the potential influence of the gut microbiome of participants to neurophysiology through two complementary strategies. The first was the analysis of the metagenome, representing the functional capacity of microbes within the gut to produce particular metabolites. The second was a confirmatory analysis of the faecal metabolome, representing the output of the combined metabolic activity of the gut microbiota. Each of these processes identified factors that were significantly associated with CI severity, and notably, positive

correlations between metabolite levels and the prevalence of genes involved in their

biosynthesis was widespread.

A lower capacity for microbial biosynthesis of the neurotransmitters, glutamate and GABA,

was evident in those with more severe CI. Levels of both factors have been associated with CI

previously (Gueli & Taibi, 2013; Jimenez-Jimenez et al., 1998; Lin et al., 2019; Lin et al.,

2017; Murley et al., 2020). The gut microbiome mediates neurological homeostasis via

multiple key pathways, including through metabolism and production of neurotransmitters,

such as glutamate, GABA, dopamine, and serotonin. These neurotransmitters can then directly

innervate intestinal neural pathways or circulate peripherally to the brain (Kaelberer et al.,

2018; Shoubridge et al., 2022; Strandwitz, 2018).

Severe CI was also associated with reduced capacity for bacterial biosynthesis of the SCFAs

butyrate, acetate, and propionate. SCFA production is known to be important for normal

cognitive function and in preventing neuroinflammation (Arnoldussen et al., 2017; Byrne et

al., 2016; Erny et al., 2015). Previous studies have identified an association between a reduced

capacity for SCFA biosynthesis and the development of a chronic and systemic inflammatory

state, commonly referred to as "inflammaging", involving increased circulation of IL-6, TNF-

α, and C-reactive protein (Franceschi & Campisi, 2014; Franceschi et al., 2018; Frasca &

Blomberg, 2016). Inflammaging, particularly in the brain, is associated with decreased

neuronal arborisation, numbers of neurons and synapses, and overall brain cortical volume

(Stephenson et al., 2018) and has been implicated in the acceleration of dementia onset (Grande

et al., 2021; Sankowski et al., 2015), and the rate of neurological deterioration (Eikelenboom

et al., 2012; Giunta et al., 2008).

In contrast to a decreased capacity for SCFA synthesis, we observed a greater capacity for methanogenesis with increasing CI severity. This relationship was apparent from the representation of methanogenic pathways within the metagenome, and from the increased relative abundance of species, such as *Methanobrevibacter smithii*, in those with severe CI. Increasing capacity for methanogenesis within the gut microbiome has been reported previously in two cohorts of centenarians (Li et al., 2022; Wu et al., 2019), as well as in rodent models of ageing (Maczulak et al., 1989). While the clinical consequences of increased methane production in the gut are poorly understood, high levels are associated with functional constipation (Chatterjee et al., 2007), diverticulosis (Weaver et al., 1986), and colon cancer (Haines et al., 1977).

The gut microbiome in participants with more severe CI was found to be depleted in its capacity to synthesise amino acids, particularly L-arginine. The availability of arginine is critical to the regulation of autophagy (Poillet-Perez et al., 2018), the cellular process that involves the recycling of nutrients from macromolecules in response to nutrient deficiency (Mizushima, 2004) and the removal of damaged material from the cellular environment (Lazarou et al., 2015). Genetic polymorphisms in genes involved in the regulation of autophagy have been linked to a number of neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and Lewy body diseases, frontotemporal dementia, and amyotrophic lateral sclerosis (Fujikake et al., 2018; Gan et al., 2018; Gao et al., 2018; Nixon, 2013; Tsuang et al., 2012). The conversion of arginine to putrescine, spermidine, and spermine by intestinal microbes promotes autophagy (Eisenberg et al., 2009; Oliphant & Allen-Vercoe, 2019; Pugin et al., 2017) and the significant reduction in arginine biosynthesis capacity is consistent with the contribution of suppressed autophagy to the development and progression of age-related disease. Severe CI was also associated with a reduced capacity for microbial production of the

essential amino acids, L-valine and L-lysine. Impaired L-valine production has been linked

with declining neurological health previously (Baranyi et al., 2016), and diet supplementation

with L-lysine and L-valine has been shown to improve cognitive and psychological function in

older adults (Suzuki et al., 2020).

Microbial functions, such as those associated with CI severity, can often be performed by many

different members of the gut microbiota. This phenomenon is referred to as functional

redundancy and can result in relationships between individual microbial species and host

measures of disease being less strong than those based on conserved microbial functional traits.

Despite this, we observed a number of discrete bacterial taxa that were significantly associated

with CI. In particular, *Methanobrevibacter smithii* and *Alistipes finegoldii* were more prevalent

in those with severe CI, while *Bacteroides uniformis* was less highly represented. As above,

Methanobrevibacter smithii is associated with higher methane production (Ghoshal et al.,

2016) and has been identified as an inflammatory and cardiometabolic biomarker (Fu et al.,

2020). Whilst the precise mechanisms of *Alistipes* species in health and disease are still unclear

(Parker et al., 2020), clinical studies of inflammatory diseases have shown *Alistipes finegoldii*

triggers intestinal inflammation and decreases SCFA-producing bacteria, potentially playing a

pathogenic role in chronic diseases (Kim et al., 2018; Parker et al., 2020; Rodriguez-Palacios

et al., 2019).

We also observed severe CI to be associated with a lower prevalence of bacterial taxa that are

considered broadly beneficial. These included *Bacteroides uniformis*, which is associated with

reduced risk of colorectal cancer (Wang et al., 2012) and inflammatory bowel disease

(Takahashi et al., 2016), and *Blautia* species, which have the potential to inhibit the growth of

pathogenic bacteria in the intestine and reduce inflammation (Hosomi et al., 2022; Liu et al.,

2021). Taxa that have been previously associated with aspects of cognition, such as *Collinsella*

aerofaciens (Ghosh et al., 2020), were more prevalent in those with severe CI. However, other

bacterial taxa associated with aspects of ageing, frailty, and cognitive decline in previous

studies, including *Faecalibacterium prausnitzii* (Jackson et al., 2016), *Eubacterium rectale*

(Ghosh et al., 2020; van Soest et al., 2020), and *Escherichia coli* (Barrientos et al., 2009;

d'Avila et al., 2018; Hoogland et al., 2018) were not associated with CI severity in our cohort.

In addition to the relative abundance of different bacterial species, analysis of the broad

structure of the gut microbiota can also be informative. We assessed three different alpha

diversity measures, Shannon-Wiener diversity, Pielou's evenness, and species richness, that

together provide an overview of microbiota structure. While evenness, which represents the

relative differences in the abundance of various species in the community, was not associated

significantly with CI severity, Shannon-Wiener diversity and species richness were both higher

in severe CI. Studies of the gut microbiota in ageing have previously reported reduced diversity

in older age. For example, Verdi and colleagues identified significantly lower faecal microbiota

diversity to be associated with longer reaction times (in cognitive assessments) in an

independently living aged cohort (Verdi et al., 2018). Similarly, Wasser and colleagues

reported reduced alpha diversity in those with Huntington's disease (Wasser et al., 2020), while

two other studies have reported no significant relationship between CI severity and alpha

diversity (Komanduri et al., 2021; Stadlbauer et al., 2020). In our analysis, where age was

adjusted for, a contrary effect was observed, consistent with an association between CI and

specific microbiome changes that is separate to wider microbial shifts that are typical in later

life.

Our study strengths and limitations include the use of entry into long term care facility

assessment tools ('ACFI') for CI ascertainment. While it has been employed by the Australian

Commonwealth Government as a basis for care funding for all residents of long term care

facilities across Australia since 2008, is completed by trained assessors, and includes the PAS-

CIS (a validated and consistently applied tool of CI in aged care), there are limitations to this

tool. For example, people may not be comprehensively assessed for CI if they have a

sensory/speech impairment, are non-English speaking, or have severe CI beyond the scope of

the instrument, which can include a concurrent diagnosis of dementia or mental disorder

(AIHW, 2002; Department of Health and Ageing, 2016). The ACFI is also designed for funding

purposes, not clinical care or epidemiological surveillance, which likely results in

underreporting of these chronic health conditions (Lind et al., 2020).

CI was measured on average 16 months prior to stool collection. There was no clinically

significant difference in mean time from assessment to stool collection between severity

groups, and the period of time between assessment and sample collection could not be reduced

further without substantial reduction in the cohort size. However, changes in cognition between

assessment and stool sample collection could confound the relationships that we report. Future

studies arising from our findings would benefit from a briefer and more consistent interval

between CI and microbiome assessment, and/or longitudinal analysis of associations.

Our study had other limitations that should be considered. First, we were able to relate changes

in intestinal microbiology to cognitive function, but not to specific aspects of host neurological

pathophysiology. Second, the relationships identified between taxonomic and functional

features of the intestinal microbiome and CI are associative and whether they contribute

directly to the development and progression of CI remains to be established. Third, the

possibility that CI severity drives alterations in microbiome composition, mediated by factors

such as dementia medications, changes in food preparation for those with dysphagia, and

isolation to locked wards for residents with severe behavioural care needs, cannot be excluded

based on the current analysis. Indeed, changes in behaviour associated with psychiatric

conditions in other contexts, particularly those relating to diet, have been shown to contribute

to disease-specific gut microbiome markers (Larroya et al., 2021).

While our analysis involved participants from five facilities in metropolitan South Australia,

the findings are likely to be representative of a wider phenomenon. Alignment of the GRACE

cohort to the comprehensive Registry of Senior Australians (ROSA) (Carpenter, 2022), a

cohort that includes over 2.8 million Australians (including those in long-term aged care)

supported the representative nature of our study cohort (Carpenter, 2022).

In conclusion, we report age-, sex-, antibiotic-, and diet-independent microbial markers of

severe CI. Our analysis implicates multiple gut microbiome-brain pathways in ageing-

associated cognitive decline, including those involved in inflammation, neurotransmission, and

autophagy. These findings raise the possibility of identifying cognitive decline and slowing its

rate of progression via microbiome-targeted therapeutic interventions.

Methods

Study design, cohort and data collection

The Generating evidence on Resistant bacteria in the Aged Care Environment (GRACE) study (www.gracestudy.com.au) was a cohort study supported by the Australian Medical Research Future Fund (Grant No. GNT1152268). Ethical approval for the study was obtained from the Southern Adelaide Clinical Human Research Ethics Committee (HREC/18/SAC/244). The GRACE study investigated the carriage and transfer of resistant bacteria in long-term aged care facilities and was conducted between 2018 and 2020. GRACE enrolled 279 residents in five long-term aged care facilities in metropolitan South Australia. Anonymised participant data, including assessments of cognition and behaviour, were collected via an entry into care funding assessment (Aged Care Funding Instrument [ACFI]), in addition to medications prescribed via the Pharmaceutical Benefits Scheme (PBS) (Carpenter, 2021).

Assessment of cognitive impairment

The *Cognitive Skills* component of the ACFI was used as a basis for assessment of cognitive impairment. This cognitive skills component assesses a person's cognitive abilities in everyday activities, including memory, self-care, and orientation (AIHW, 2002; Department of Health and Ageing, 2016), as defined via the Psychogeriatric Assessment Scales – Cognitive Impairment Scales (PAS-CIS) method (Jorm et al., 1995). Where individuals were unable to undertake the PAS-CIS test, for example, non-English speaking, sensory impairment, or severe cognitive impairment beyond the scope of the instrument, the ACFI cognitive skills assessment was based on a clinical report by a registered health professional (Department of Health and Ageing, 2016). The ACFI cognitive skills component utilised the PAS-CIS and/or clinical reports to rate an individual's level of cognitive impairment as none or minimal (PAS-CIS = 0-3), mild (4-9), moderate (10-15), or severe (16-21).

Cognitive impairment cohort

GRACE participants were categorised according to their cognitive skills rating, as defined in the ACFI. Participants were excluded if: 1) their cognitive skills assessment was not completed or missing, 2) the date of stool collection was not known, 3) the date of the cognitive assessment was not known, 4) the participant was diagnosed with a developmental or intellectual disability, or 5) the period between cognitive skills assessment and stool sample collection was not known or was deemed an outlier (>1462 days as determined using the ROUT method of regression and outlier removal (Motulsky & Brown, 2006)). A total of 45 participants were excluded (detailed in **Supplementary Fig. 1**). Participants with dementia and a missing PAS-CIS rating were imputed the median PAS-CIS value from their cognitive skills assessment group. Mental and behavioural diagnoses of dementia, depression, and delirium were ascertained from the ACFI, where a documented diagnosis from a medical practitioner was provided.

Faecal collection, DNA extraction, metagenomic sequencing and bioinformatics

Stool was collected and stored using Norgen Stool Nucleic Acid Collection and Preservation Tubes (Norgen Biotek, ON, Canada) and microbial DNA extracted using the PowerLyzer PowerSoil DNA Isolation Kit (Qiagen, Hilden, Germany) as described previously (Carpenter, 2021). Indexed, paired-end DNA libraries were prepared using the Nextera XT DNA Library Prep Kit (Illumina, CA, USA), as per manufacturer's instructions. Samples were sequenced at a depth of 5 Gb on an Illumina Novaseq platform with 150bp paired-end reads. Forward and reverse sequences were quality-filtered using Trimmomatic (v0.39) and human reads were removed with Bowtie (v2.3.5.1) against the NCBI human reference genome release GRCh38 (Bolger et al., 2014; Langmead & Salzberg, 2012). Taxonomic relative abundance was assigned using MetaPhlAn (v3.0) (Beghini et al., 2021), while microbial metabolic pathway

abundance was assigned using HUMAnN (v3.0) against the MetaCyc database (Beghini et al.,

2021). Sequence data has been entered into the European Nucleotide Archive (ENA) at EMBL-

EBI under accession number PRJEB51408.

Microbiome characterisation

The taxonomic relative abundance at the species level was used to generate alpha diversity

(within-group) and beta diversity (between-group) measures. Alpha diversity measures

included Pielou's evenness (J': a score between 0-1 where scores are influenced more by the

evenness of abundant species), the Shannon-Wiener diversity (H'): a score of the number and

equal representation of different types of species (Peet, 1974), and species richness (d: total

number of unique species identified per participant), and were generated using the 'vegan' R

package (Oksanen, 2022).

The Bray-Curtis index was calculated to compare microbiome similarity between groups (beta

diversity), using square-root transformed species relative abundance data (PRIMER 6

(v6.1.16)). For sensitivity analysis, weighted and unweighted UniFrac distance matrices

(Lozupone & Knight, 2005) were calculated using the "calculate_unifrac" MetaPhlAn R script

(Beghini et al., 2021). Non-metric multidimensional scaling (nMDS) plots for all beta diversity

measures were generated using the 'vegan' package in R and visualised using 'ggplot2'.

Microbial functional profiling

The functional capacity of the gut microbiota was defined by the genetically encoded functional

traits detected within the metagenome. These MetaCyc pathways from HUMAnN were filtered

to only analyse those present in >30% of participants. Two functional profiling analyses were

performed: an untargeted analysis of all filtered pathways (n=400), and a targeted analysis

based on pathways with a hypothesised functional role in cognitive impairment (n=70). These included pathways involved in neurotransmitter biosynthesis (n=2), SCFA production (n=25), and amino acid biosynthesis (n=43).

Metabolite profiling

As a confirmatory analysis of microbial functional capacity, the metabolomic profile of a randomly selected subgroup of individuals (n=35; n=11-12/group) was established. Stool metabolite analysis was performed on an Agilent 1200 series high-performance liquid chromatography system (Agilent Technologies) (methods modified from (Gubert et al., 2022; Kong et al., 2021) and detailed in **Supplementary Text 1**). Briefly, metabolite extraction and analysis were performed separately for SCFAs and polar metabolites. SCFAs analysis was performed using an Agilent 6490 series triple quadrupole mass spectrometer (Agilent Technologies) while polar metabolites (a screen for 165 low molecular weight metabolites, e.g. amino acids) were analysed using an Agilent 6545 series quadrupole time-of-flight mass spectrometer (Agilent Technologies). Resultant data matrices were imported to the web-based platform MetaboAnalyst (v5.0) for quality control checks. SCFA data were normalised to internal standards, and polar metabolite data were log-transformed and median-normalised.

Covariates

Covariates were: days since cognitive assessment (below or equal/above the median), age (low, medium or high tertile), sex (male or female), medication history (Pharmaceutical Benefits Scheme (PBS) data available or unavailable), medications that affect gastrointestinal health and are prevalent in aged care facilities: antibiotic use (yes or no); proton pump inhibitor use (yes or no); opioid use (yes or no); laxative use (yes or no), meal texture at time of cognitive assessment (regular or soft/smooth), and liquid texture at time of cognitive assessment

(normal/thin or thick). Medication use was defined as two or more supplies to a resident within

90 days prior to stool collection.

Statistical analysis

Both unadjusted and multivariate regression models were applied in all analyses. Multivariate

adjusted models accounted for time between cognitive assessment and stool collection, age,

sex, antibiotics, proton pump inhibitors, opioids, laxatives, meal texture, and liquid texture (as

detailed above).

Beta diversity analysis was performed using permutational multivariate analyses of variance

(PERMANOVA) on Bray-Curtis, weighted, and unweighted UniFrac distance matrices in an

unrestricted permutation of raw data. Only the Bray-Curtis metric was assessed with the

multivariate-adjusted model. PERMANOVA analyses were performed using PRIMER 6, with

9999 permutations.

Within-individual microbiome variables included alpha diversity, phyla-level relative

abundance (only those detected in >30% of participants), species-level relative abundance

(only those detected in >30% of participants), metabolic pathway abundance (only those

detected in >30% of participants), and metabolite intensities. All within-individual variables

were converted to groups consisting of: zero values, tertile 1, tertile 2, and tertile 3. Ordinal

logistic regression was performed to assess the effect of CI on microbiome variables using

the 'MASS' function in R. The odds ratios and 95% confidence intervals for the coefficients

of the regression models were calculated and tested for statistical significance ($p < 0.05$) as CI

severity increased, using the PAS-CIS score of cognitive impairment as the predictor

variable. False Discovery Rate (FDR) multiple hypothesis testing was conducted with the

Benjamini and Hochberg method across all profiles using the 'p.adjust' function in R, at a

significant threshold of 0.05. Correlations between microbial functional capacity and detected

metabolites were calculated by two-tailed Spearman correlations and tested for statistical

significance ($p < 0.05$).

Ethics approval and consent to participate

Ethical approval for the study was obtained from the Southern Adelaide Clinical Human Research Ethics Committee (HREC/18/SAC/244). Participants provided written informed consent themselves or where third-party consent was required, a legal guardian or family member with power of attorney provided consent on their behalf.

Declaration of interests

The authors declare that they have no competing interests, nor any financial or personal relationships with other people or organisations that could bias this study.

Funding

This research was supported by an Australian Medical Research Future Fund (MRFF) grant from the Australian Department of Health (GNT1152268). The Australian Department of Health reviewed the study proposal, but did not play a role in study design, data collection, analysis, interpretation, or manuscript writing. GBR is supported by a National Health and Medical Research Council (NHMRC) Senior Research Fellowship (GNT119378) and a Matthew Flinders Professorial Fellowship. MCI is supported by The Hospital Research Foundation Mid-Career Fellowship (MCF-27-2019) and NHMRC Investigator Grant (GNT119378). DJL is supported by an EMBL Australia Group Leader Award. SLT is supported by an NHMRC Emerging Leadership grant (GNT2008625).

Acknowledgments

This project used NCRIS-enabled Metabolomics Australia infrastructure at the University of Melbourne funded through BioPlatforms Australia.

References

Australian Institute of Health and Welfare (AIHW). (2002). *Aged care assessment program data dictionary*. Canberra, Australia.

Albert, M. S., Jones, K., Savage, C. R., Berkman, L., Seeman, T., Blazer, D., & Rowe, J. W. (1995). Predictors of cognitive change in older persons: MacArthur studies of successful aging. *Psychol Aging*, *10*(4), 578-589. https://doi.org/10.1037//0882-7974.10.4.578

Arentsen, T., Qian, Y., Gkotzis, S., Femenia, T., Wang, T., Udekwu, K., Forssberg, H., & Diaz Heijtz, R. (2017). The bacterial peptidoglycan-sensing molecule Pglyrp2 modulates brain development and behavior. *Mol Psychiatry*, *22*(2), 257-266. https://doi.org/10.1038/mp.2016.182

Arnoldussen, I. A. C., Wiesmann, M., Pelgrim, C. E., Wielemaker, E. M., van Duyvenvoorde, W., Amaral-Santos, P. L., Verschuren, L., Keijser, B. J. F., Heerschap, A., Kleemann, R., Wielinga, P. Y., & Kiliaan, A. J. (2017). Butyrate restores HFD-induced adaptations in brain function and metabolism in mid-adult obese mice. *Int J Obes (Lond)*, *41*(6), 935-944. https://doi.org/10.1038/ijo.2017.52

Baranyi, A., Amouzadeh-Ghadikolai, O., von Lewinski, D., Rothenhausler, H. B., Theokas, S., Robier, C., Mangge, H., Reicht, G., Hlade, P., & Meinitzer, A. (2016). Branched-Chain Amino Acids as New Biomarkers of Major Depression - A Novel Neurobiology of Mood Disorder. *PLoS One*, *11*(8), e0160542. https://doi.org/10.1371/journal.pone.0160542

Barrientos, R. M., Watkins, L. R., Rudy, J. W., & Maier, S. F. (2009). Characterization of the sickness response in young and aging rats following E. coli infection. *Brain Behav Immun*, *23*(4), 450-454. https://doi.org/10.1016/j.bbi.2009.01.016

Beghini, F., McIver, L. J., Blanco-Miguez, A., Dubois, L., Asnicar, F., Maharjan, S., Mailyan, A., Manghi, P., Scholz, M., Thomas, A. M., Valles-Colomer, M., Weingart, G., Zhang, Y., Zolfo, M., Huttenhower, C., Franzosa, E. A., & Segata, N. (2021). Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3. *Elife*, *10*. https://doi.org/10.7554/eLife.65088

Bellono, N. W., Bayrer, J. R., Leitch, D. B., Castro, J., Zhang, C., O'Donnell, T. A., Brierley, S. M., Ingraham, H. A., & Julius, D. (2017). Enterochromaffin Cells Are Gut Chemosensors that Couple to Sensory Neural Pathways. *Cell*, *170*(1), 185-198 e116. https://doi.org/10.1016/j.cell.2017.05.034

Bjorkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., Magnusson, A., Woodman, B., Landles, C., Pouladi, M. A., Hayden, M. R., Khalili-Shirazi, A., Lowdell, M. W., Brundin, P., Bates, G. P., Leavitt, B. R., Moller, T., & Tabrizi, S. J. (2008). A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. *J Exp Med*, *205*(8), 1869-1877. https://doi.org/10.1084/jem.20080178

Bolger, A. M., Lohse, M., & Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics*, *30*(15), 2114-2120. https://doi.org/10.1093/bioinformatics/btu170

Bonfili, L., Cecarini, V., Gogoi, O., Gong, C., Cuccioloni, M., Angeletti, M., Rossi, G., & Eleuteri, A. M. (2021). Microbiota modulation as preventative and therapeutic approach in Alzheimer's disease. *FEBS J*, *288*(9), 2836-2855. https://doi.org/10.1111/febs.15571

Bussian, T. J., Aziz, A., Meyer, C. F., Swenson, B. L., van Deursen, J. M., & Baker, D. J. (2018). Clearance of senescent glial cells prevents tau-dependent pathology and

cognitive decline. *Nature*, *562*(7728), 578-582. https://doi.org/10.1038/s41586-018-0543-y

Byrne, C. S., Chambers, E. S., Alhabeeb, H., Chhina, N., Morrison, D. J., Preston, T., Tedford, C., Fitzpatrick, J., Irani, C., Busza, A., Garcia-Perez, I., Fountana, S., Holmes, E., Goldstone, A. P., & Frost, G. S. (2016). Increased colonic propionate reduces anticipatory reward responses in the human striatum to high-energy foods. *Am J Clin Nutr*, *104*(1), 5-14. https://doi.org/10.3945/ajcn.115.126706

Carpenter, L., Shoubridge, A., Flynn, E., Taylor, S. Ivey, K., Rogers, G. on behalf of the GRACE Investigative Study Team. (2021). *Generating evidence on Resistant Bacteria in the Aged Care Environment (GRACE) 2021 Report*. SAHMRI. https://www.gracestudy.com.au/post/grace-study-stage-2-report

Carpenter, L., Shoubridge, A.P., Flynn, E., Lang, C., Taylor, S., Papanicolas, L., Collins, J., Gordon, D., Lynn, D. J., Crotty, M., Whitehead, C., Leong, L., Wesselingh, S., Ivey, K., Inacio, M. C., Rogers G. B. (2022). Cohort Profile: The Australian Generating evidence on antimicrobial resistance in the aged care environment (GRACE) study; alignment with national population characteristics. *medRxiv*. https://doi.org/10.1101/2022.10.26.22281199

Chatterjee, S., Park, S., Low, K., Kong, Y., & Pimentel, M. (2007). The degree of breath methane production in IBS correlates with the severity of constipation. *Am J Gastroenterol*, *102*(4), 837-841. https://doi.org/10.1111/j.1572-0241.2007.01072.x

Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., Stanton, C., van Sinderen, D., O'Connor, M., Harnedy, N., O'Connor, K., Henry, C., O'Mahony, D., Fitzgerald, A. P., Shanahan, F., Twomey, C., Hill, C., Ross, R. P., & O'Toole, P. W. (2011). Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A*, *108 Suppl 1*, 4586-4591. https://doi.org/10.1073/pnas.1000097107

Comijs, H. C., Dik, M. G., Deeg, D. J., & Jonker, C. (2004). The course of cognitive decline in older persons: results from the longitudinal aging study amsterdam. *Dement Geriatr Cogn Disord*, *17*(3), 136-142. https://doi.org/10.1159/000076346

Correa-Oliveira, R., Fachi, J. L., Vieira, A., Sato, F. T., & Vinolo, M. A. (2016). Regulation of immune cell function by short-chain fatty acids. *Clin Transl Immunology*, *5*(4), e73. https://doi.org/10.1038/cti.2016.17

Cryan, J. F., O'Riordan, K. J., Cowan, C. S. M., Sandhu, K. V., Bastiaanssen, T. F. S., Boehme, M., Codagnone, M. G., Cussotto, S., Fulling, C., Golubeva, A. V., Guzzetta, K. E., Jaggar, M., Long-Smith, C. M., Lyte, J. M., Martin, J. A., Molinero-Perez, A., Moloney, G., Morelli, E., Morillas, E., O'Connor, R., Cruz-Pereira, J. S., Peterson, V. L., Rea, K., Ritz, N. L., Sherwin, E., Spichak, S., Teichman, E. M., van de Wouw, M., Ventura-Silva, A. P., Wallace-Fitzsimons, S. E., Hyland, N., Clarke, G., & Dinan, T. G. (2019). The Microbiota-Gut-Brain Axis. *Physiol Rev*, *99*(4), 1877-2013. https://doi.org/10.1152/physrev.00018.2018

D'Amato, A., Di Cesare Mannelli, L., Lucarini, E., Man, A. L., Le Gall, G., Branca, J. J. V., Ghelardini, C., Amedei, A., Bertelli, E., Regoli, M., Pacini, A., Luciani, G., Gallina, P., Altera, A., Narbad, A., Gulisano, M., Hoyles, L., Vauzour, D., & Nicoletti, C. (2020). Faecal microbiota transplant from aged donor mice affects spatial learning and memory via modulating hippocampal synaptic plasticity- and neurotransmission-related proteins in young recipients. *Microbiome*, *8*(1), 140. https://doi.org/10.1186/s40168-020-00914-w

d'Avila, J. C., Siqueira, L. D., Mazeraud, A., Azevedo, E. P., Foguel, D., Castro-Faria-Neto, H. C., Sharshar, T., Chretien, F., & Bozza, F. A. (2018). Age-related cognitive impairment is associated with long-term neuroinflammation and oxidative stress in a

mouse model of episodic systemic inflammation. *J Neuroinflammation*, *15*(1), 28. https://doi.org/10.1186/s12974-018-1059-y

Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019). The role of short-chain fatty acids in microbiota-gut-brain communication. *Nat Rev Gastroenterol Hepatol*, *16*(8), 461-478. https://doi.org/10.1038/s41575-019-0157-3

Department of Health and Ageing. (2016). *Aged care funding instrument (ACFI) user guide*. Canberra, Australia.

Desbonnet, L., Clarke, G., Traplin, A., O'Sullivan, O., Crispie, F., Moloney, R. D., Cotter, P. D., Dinan, T. G., & Cryan, J. F. (2015). Gut microbiota depletion from early adolescence in mice: Implications for brain and behaviour. *Brain Behav Immun*, *48*, 165-173. https://doi.org/10.1016/j.bbi.2015.04.004

Du, G., Dong, W., Yang, Q., Yu, X., Ma, J., Gu, W., & Huang, Y. (2020). Altered Gut Microbiota Related to Inflammatory Responses in Patients With Huntington's Disease. *Front Immunol*, *11*, 603594. https://doi.org/10.3389/fimmu.2020.603594

Eikelenboom, P., Hoozemans, J. J., Veerhuis, R., van Exel, E., Rozemuller, A. J., & van Gool, W. A. (2012). Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. *Alzheimers Res Ther*, *4*(3), 15. https://doi.org/10.1186/alzrt118

Eisenberg, T., Knauer, H., Schauer, A., Buttner, S., Ruckenstuhl, C., Carmona-Gutierrez, D., Ring, J., Schroeder, S., Magnes, C., Antonacci, L., Fussi, H., Deszcz, L., Hartl, R., Schraml, E., Criollo, A., Megalou, E., Weiskopf, D., Laun, P., Heeren, G., Breitenbach, M., Grubeck-Loebenstein, B., Herker, E., Fahrenkrog, B., Frohlich, K. U., Sinner, F., Tavernarakis, N., Minois, N., Kroemer, G., & Madeo, F. (2009). Induction of autophagy by spermidine promotes longevity. *Nat Cell Biol*, *11*(11), 1305-1314. https://doi.org/10.1038/ncb1975

Erny, D., Hrabe de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., Schwierzeck, V., Utermohlen, O., Chun, E., Garrett, W. S., McCoy, K. D., Diefenbach, A., Staeheli, P., Stecher, B., Amit, I., & Prinz, M. (2015). Host microbiota constantly control maturation and function of microglia in the CNS. *Nat Neurosci*, *18*(7), 965-977. https://doi.org/10.1038/nn.4030

Franceschi, C., & Campisi, J. (2014). Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. *J Gerontol A Biol Sci Med Sci*, *69 Suppl 1*, S4-9. https://doi.org/10.1093/gerona/glu057

Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: a new immune-metabolic viewpoint for age-related diseases. *Nat Rev Endocrinol*, *14*(10), 576-590. https://doi.org/10.1038/s41574-018-0059-4

Frasca, D., & Blomberg, B. B. (2016). Inflammaging decreases adaptive and innate immune responses in mice and humans. *Biogerontology*, *17*(1), 7-19. https://doi.org/10.1007/s10522-015-9578-8

Frohlich, E. E., Farzi, A., Mayerhofer, R., Reichmann, F., Jacan, A., Wagner, B., Zinser, E., Bordag, N., Magnes, C., Frohlich, E., Kashofer, K., Gorkiewicz, G., & Holzer, P. (2016). Cognitive impairment by antibiotic-induced gut dysbiosis: Analysis of gut microbiota-brain communication. *Brain Behav Immun*, *56*, 140-155. https://doi.org/10.1016/j.bbi.2016.02.020

Fu, B. C., Hullar, M. A. J., Randolph, T. W., Franke, A. A., Monroe, K. R., Cheng, I., Wilkens, L. R., Shepherd, J. A., Madeleine, M. M., Le Marchand, L., Lim, U., & Lampe, J. W. (2020). Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. *Am J Clin Nutr*, *111*(6), 1226-1234. https://doi.org/10.1093/ajcn/nqaa015

Fujikake, N., Shin, M., & Shimizu, S. (2018). Association Between Autophagy and Neurodegenerative Diseases. *Front Neurosci*, *12*, 255. https://doi.org/10.3389/fnins.2018.00255

Gan, L., Cookson, M. R., Petrucelli, L., & La Spada, A. R. (2018). Converging pathways in neurodegeneration, from genetics to mechanisms. *Nat Neurosci*, *21*(10), 1300-1309. https://doi.org/10.1038/s41593-018-0237-7

Gao, S., Casey, A. E., Sargeant, T. J., & Makinen, V. P. (2018). Genetic variation within endolysosomal system is associated with late-onset Alzheimer's disease. *Brain*, *141*(9), 2711-2720. https://doi.org/10.1093/brain/awy197

Ghosh, T. S., Rampelli, S., Jeffery, I. B., Santoro, A., Neto, M., Capri, M., Giampieri, E., Jennings, A., Candela, M., Turroni, S., Zoetendal, E. G., Hermes, G. D. A., Elodie, C., Meunier, N., Brugere, C. M., Pujos-Guillot, E., Berendsen, A. M., De Groot, L., Feskins, E. J. M., Kaluza, J., Pietruszka, B., Bielak, M. J., Comte, B., Maijo-Ferre, M., Nicoletti, C., De Vos, W. M., Fairweather-Tait, S., Cassidy, A., Brigidi, P., Franceschi, C., & O'Toole, P. W. (2020). Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. *Gut*, *69*(7), 1218-1228. https://doi.org/10.1136/gutjnl-2019-319654

Ghoshal, U., Shukla, R., Srivastava, D., & Ghoshal, U. C. (2016). Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in Methanobrevibacter smithii, Which Is Associated with Higher Methane Production. *Gut Liver*, *10*(6), 932-938. https://doi.org/10.5009/gnl15588

Giunta, B., Fernandez, F., Nikolic, W. V., Obregon, D., Rrapo, E., Town, T., & Tan, J. (2008). Inflammaging as a prodrome to Alzheimer's disease. *J Neuroinflammation*, *5*, 51. https://doi.org/10.1186/1742-2094-5-51

Grande, G., Marengoni, A., Vetrano, D. L., Roso-Llorach, A., Rizzuto, D., Zucchelli, A., Qiu, C., Fratiglioni, L., & Calderon-Larranaga, A. (2021). Multimorbidity burden and dementia risk in older adults: The role of inflammation and genetics. *Alzheimers Dement*, *17*(5), 768-776. https://doi.org/10.1002/alz.12237

Gubert, C., Choo, J. M., Love, C. J., Kodikara, S., Masson, B. A., Liew, J. J. M., Wang, Y., Kong, G., Narayana, V. K., Renoir, T., Le Cao, K. A., Rogers, G. B., & Hannan, A. J. (2022). Faecal microbiota transplant ameliorates gut dysbiosis and cognitive deficits in Huntington's disease mice. *Brain Commun*, *4*(4), fcac205. https://doi.org/10.1093/braincomms/fcac205

Gueli, M. C., & Taibi, G. (2013). Alzheimer's disease: amino acid levels and brain metabolic status. *Neurol Sci*, *34*(9), 1575-1579. https://doi.org/10.1007/s10072-013-1289-9

Haines, A., Metz, G., Dilawari, J., Blendis, L., & Wiggins, H. (1977). Breath-methane in patients with cancer of the large bowel. *Lancet*, *2*(8036), 481-483. https://doi.org/10.1016/s0140-6736(77)91605-1

Harada, C. N., Natelson Love, M. C., & Triebel, K. L. (2013). Normal cognitive aging. *Clin Geriatr Med*, *29*(4), 737-752. https://doi.org/10.1016/j.cger.2013.07.002

Henon, H., Durieu, I., Guerouaou, D., Lebert, F., Pasquier, F., & Leys, D. (2001). Poststroke dementia: incidence and relationship to prestroke cognitive decline. *Neurology*, *57*(7), 1216-1222. https://doi.org/10.1212/wnl.57.7.1216

Hoogland, I. C. M., Westhoff, D., Engelen-Lee, J. Y., Melief, J., Valls Seron, M., Houben-Weerts, J., Huitinga, I., van Westerloo, D. J., van der Poll, T., van Gool, W. A., & van de Beek, D. (2018). Microglial Activation After Systemic Stimulation With Lipopolysaccharide and Escherichia coli. *Front Cell Neurosci*, *12*, 110. https://doi.org/10.3389/fncel.2018.00110

Hosomi, K., Saito, M., Park, J., Murakami, H., Shibata, N., Ando, M., Nagatake, T., Konishi, K., Ohno, H., Tanisawa, K., Mohsen, A., Chen, Y. A., Kawashima, H., Natsume-Kitatani, Y., Oka, Y., Shimizu, H., Furuta, M., Tojima, Y., Sawane, K., Saika, A., Kondo, S., Yonejima, Y., Takeyama, H., Matsutani, A., Mizuguchi, K., Miyachi, M., & Kunisawa, J. (2022). Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota. *Nat Commun*, *13*(1), 4477. https://doi.org/10.1038/s41467-022-32015-7

Jackson, M. A., Jeffery, I. B., Beaumont, M., Bell, J. T., Clark, A. G., Ley, R. E., O'Toole, P. W., Spector, T. D., & Steves, C. J. (2016). Signatures of early frailty in the gut microbiota. *Genome Med*, *8*(1), 8. https://doi.org/10.1186/s13073-016-0262-7

Jimenez-Jimenez, F. J., Molina, J. A., Gomez, P., Vargas, C., de Bustos, F., Benito-Leon, J., Tallon-Barranco, A., Orti-Pareja, M., Gasalla, T., & Arenas, J. (1998). Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease. *J Neural Transm (Vienna)*, *105*(2-3), 269-277. https://doi.org/10.1007/s007020050056

Jorm, A. F., Mackinnon, A. J., Henderson, A. S., Scott, R., Christensen, H., Korten, A. E., Cullen, J. S., & Mulligan, R. (1995). The Psychogeriatric Assessment Scales: a multi-dimensional alternative to categorical diagnoses of dementia and depression in the elderly. *Psychol Med*, *25*(3), 447-460. https://doi.org/10.1017/s0033291700033377

Kaelberer, M. M., Buchanan, K. L., Klein, M. E., Barth, B. B., Montoya, M. M., Shen, X., & Bohorquez, D. V. (2018). A gut-brain neural circuit for nutrient sensory transduction. *Science*, *361*(6408). https://doi.org/10.1126/science.aat5236

Kim, M. H., Kang, S. G., Park, J. H., Yanagisawa, M., & Kim, C. H. (2013). Short-chain fatty acids activate GPR41 and GPR43 on intestinal epithelial cells to promote inflammatory responses in mice. *Gastroenterology*, *145*(2), 396-406 e391-310. https://doi.org/10.1053/j.gastro.2013.04.056

Kim, M. S., Kim, Y., Choi, H., Kim, W., Park, S., Lee, D., Kim, D. K., Kim, H. J., Choi, H., Hyun, D. W., Lee, J. Y., Choi, E. Y., Lee, D. S., Bae, J. W., & Mook-Jung, I. (2020). Transfer of a healthy microbiota reduces amyloid and tau pathology in an Alzheimer's disease animal model. *Gut*, *69*(2), 283-294. https://doi.org/10.1136/gutjnl-2018-317431

Kim, S., Goel, R., Kumar, A., Qi, Y., Lobaton, G., Hosaka, K., Mohammed, M., Handberg, E. M., Richards, E. M., Pepine, C. J., & Raizada, M. K. (2018). Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. *Clin Sci (Lond)*, *132*(6), 701-718. https://doi.org/10.1042/CS20180087

Koistinaho, M., Lin, S., Wu, X., Esterman, M., Koger, D., Hanson, J., Higgs, R., Liu, F., Malkani, S., Bales, K. R., & Paul, S. M. (2004). Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. *Nat Med*, *10*(7), 719-726. https://doi.org/10.1038/nm1058

Komanduri, M., Savage, K., Lea, A., McPhee, G., Nolidin, K., Deleuil, S., Stough, C., & Gondalia, S. (2021). The Relationship between Gut Microbiome and Cognition in Older Australians. *Nutrients*, *14*(1). https://doi.org/10.3390/nu14010064

Kong, G., Ellul, S., Narayana, V. K., Kanojia, K., Ha, H. T. T., Li, S., Renoir, T., Cao, K. L., & Hannan, A. J. (2021). An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington's disease. *Neurobiol Dis*, *148*, 105199. https://doi.org/10.1016/j.nbd.2020.105199

Lai, W. T., Zhao, J., Xu, S. X., Deng, W. F., Xu, D., Wang, M. B., He, F. S., Liu, Y. H., Guo, Y. Y., Ye, S. W., Yang, Q. F., Zhang, Y. L., Wang, S., Li, M. Z., Yang, Y. J., Liu, T. B., Tan, Z. M., Xie, X. H., & Rong, H. (2021). Shotgun metagenomics reveals both taxonomic and tryptophan pathway differences of gut microbiota in bipolar disorder

with current major depressive episode patients. *J Affect Disord*, *278*, 311-319. https://doi.org/10.1016/j.jad.2020.09.010

Langmead, B., & Salzberg, S. L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat Methods*, *9*(4), 357-359. https://doi.org/10.1038/nmeth.1923

Larroya, A., Pantoja, J., Codoner-Franch, P., & Cenit, M. C. (2021). Towards Tailored Gut Microbiome-Based and Dietary Interventions for Promoting the Development and Maintenance of a Healthy Brain. *Front Pediatr*, *9*, 705859. https://doi.org/10.3389/fped.2021.705859

Lazarou, M., Sliter, D. A., Kane, L. A., Sarraf, S. A., Wang, C., Burman, J. L., Sideris, D. P., Fogel, A. I., & Youle, R. J. (2015). The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. *Nature*, *524*(7565), 309-314. https://doi.org/10.1038/nature14893

Li, C., Luan, Z., Zhao, Y., Chen, J., Yang, Y., Wang, C., Jing, Y., Qi, S., Li, Z., Guo, H., Xu, W., Zhao, B., Wu, C., Wang, S., Yang, Y., & Sun, G. (2022). Deep insights into the gut microbial community of extreme longevity in south Chinese centenarians by ultra-deep metagenomics and large-scale culturomics. *NPJ Biofilms Microbiomes*, *8*(1), 28. https://doi.org/10.1038/s41522-022-00282-3

Lin, C. H., Yang, H. T., & Lane, H. Y. (2019). D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer's disease or mild cognitive impairment. *Pharmacol Biochem Behav*, *185*, 172760. https://doi.org/10.1016/j.pbb.2019.172760

Lin, C. H., Yang, S. Y., Horng, H. E., Yang, C. C., Chieh, J. J., Chen, H. H., Liu, B. H., & Chiu, M. J. (2017). Plasma alpha-synuclein predicts cognitive decline in Parkinson's disease. *J Neurol Neurosurg Psychiatry*, *88*(10), 818-824. https://doi.org/10.1136/jnnp-2016-314857

Lin, Y. T., Seo, J., Gao, F., Feldman, H. M., Wen, H. L., Penney, J., Cam, H. P., Gjoneska, E., Raja, W. K., Cheng, J., Rueda, R., Kritskiy, O., Abdurrob, F., Peng, Z., Milo, B., Yu, C. J., Elmsaouri, S., Dey, D., Ko, T., Yankner, B. A., & Tsai, L. H. (2018). APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. *Neuron*, *98*(6), 1141-1154 e1147. https://doi.org/10.1016/j.neuron.2018.05.008

Lind, K. E., Raban, M. Z., Brett, L., Jorgensen, M. L., Georgiou, A., & Westbrook, J. I. (2020). Measuring the prevalence of 60 health conditions in older Australians in residential aged care with electronic health records: a retrospective dynamic cohort study. *Popul Health Metr*, *18*(1), 25. https://doi.org/10.1186/s12963-020-00234-z

Liu, C. C., Zhao, N., Fu, Y., Wang, N., Linares, C., Tsai, C. W., & Bu, G. (2017). ApoE4 Accelerates Early Seeding of Amyloid Pathology. *Neuron*, *96*(5), 1024-1032 e1023. https://doi.org/10.1016/j.neuron.2017.11.013

Liu, X., Mao, B., Gu, J., Wu, J., Cui, S., Wang, G., Zhao, J., Zhang, H., & Chen, W. (2021). Blautia-a new functional genus with potential probiotic properties? *Gut Microbes*, *13*(1), 1-21. https://doi.org/10.1080/19490976.2021.1875796

Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., Costafreda, S. G., Dias, A., Fox, N., Gitlin, L. N., Howard, R., Kales, H. C., Kivimaki, M., Larson, E. B., Ogunniyi, A., Orgeta, V., Ritchie, K., Rockwood, K., Sampson, E. L., Samus, Q., Schneider, L. S., Selbaek, G., Teri, L., & Mukadam, N. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*, *396*(10248), 413-446. https://doi.org/10.1016/S0140-6736(20)30367-6

Lozupone, C., & Knight, R. (2005). UniFrac: a new phylogenetic method for comparing microbial communities. *Appl Environ Microbiol*, *71*(12), 8228-8235. https://doi.org/10.1128/AEM.71.12.8228-8235.2005

Luo, R., Su, L. Y., Li, G., Yang, J., Liu, Q., Yang, L. X., Zhang, D. F., Zhou, H., Xu, M., Fan, Y., Li, J., & Yao, Y. G. (2020). Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. *Autophagy*, *16*(1), 52-69. https://doi.org/10.1080/15548627.2019.1596488

Lynn, M. A., Eden, G., Ryan, F. J., Bensalem, J., Wang, X., Blake, S. J., Choo, J. M., Chern, Y. T., Sribnaia, A., James, J., Benson, S. C., Sandeman, L., Xie, J., Hassiotis, S., Sun, E. W., Martin, A. M., Keller, M. D., Keating, D. J., Sargeant, T. J., Proud, C. G., Wesselingh, S. L., Rogers, G. B., & Lynn, D. J. (2021). The composition of the gut microbiota following early-life antibiotic exposure affects host health and longevity in later life. *Cell Rep*, *36*(8), 109564. https://doi.org/10.1016/j.celrep.2021.109564

Maczulak, A. E., Wolin, M. J., & Miller, T. L. (1989). Increase in colonic methanogens and total anaerobes in aging rats. *Appl Environ Microbiol*, *55*(10), 2468-2473. https://doi.org/10.1128/aem.55.10.2468-2473.1989

Manderino, L., Carroll, I., Azcarate-Peril, M. A., Rochette, A., Heinberg, L., Peat, C., Steffen, K., Mitchell, J., & Gunstad, J. (2017). Preliminary Evidence for an Association Between the Composition of the Gut Microbiome and Cognitive Function in Neurologically Healthy Older Adults. *J Int Neuropsychol Soc*, *23*(8), 700-705. https://doi.org/10.1017/S1355617717000492

Marx, W., McGuinness, A. J., Rocks, T., Ruusunen, A., Cleminson, J., Walker, A. J., Gomes-da-Costa, S., Lane, M., Sanches, M., Diaz, A. P., Tseng, P. T., Lin, P. Y., Berk, M., Clarke, G., O'Neil, A., Jacka, F., Stubbs, B., Carvalho, A. F., Quevedo, J., Soares, J. C., & Fernandes, B. S. (2021). The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies. *Mol Psychiatry*, *26*(8), 4158-4178. https://doi.org/10.1038/s41380-020-00951-9

Mattila, P. M., Rinne, J. O., Helenius, H., Dickson, D. W., & Roytta, M. (2000). Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease. *Acta Neuropathol*, *100*(3), 285-290. https://doi.org/10.1007/s004019900168

Meyer, K., Lulla, A., Debroy, K., Shikany, J. M., Yaffe, K., Meirelles, O., & Launer, L. J. (2022). Association of the Gut Microbiota With Cognitive Function in Midlife. *JAMA Netw Open*, *5*(2), e2143941. https://doi.org/10.1001/jamanetworkopen.2021.43941

Mizushima, N. (2004). Methods for monitoring autophagy. *Int J Biochem Cell Biol*, *36*(12), 2491-2502. https://doi.org/10.1016/j.biocel.2004.02.005

Motulsky, H. J., & Brown, R. E. (2006). Detecting outliers when fitting data with nonlinear regression - a new method based on robust nonlinear regression and the false discovery rate. *BMC Bioinformatics*, *7*, 123. https://doi.org/10.1186/1471-2105-7-123

Murley, A. G., Rouse, M. A., Jones, P. S., Ye, R., Hezemans, F. H., O'Callaghan, C., Frangou, P., Kourtzi, Z., Rua, C., Carpenter, T. A., Rodgers, C. T., & Rowe, J. B. (2020). GABA and glutamate deficits from frontotemporal lobar degeneration are associated with disinhibition. *Brain*, *143*(11), 3449-3462. https://doi.org/10.1093/brain/awaa305

Nixon, R. A. (2013). The role of autophagy in neurodegenerative disease. *Nat Med*, *19*(8), 983-997. https://doi.org/10.1038/nm.3232

Oksanen, J., Simpson, G. L., Blanchet, F. G., Kindt, R., Legendre, P., Minchin, P. R., O'Hara, R. B., Solymos, P., Stevens, M. H., Szoecs, E., Wagner, H., Barbour, M., Bedward, M., Bolker, B., Borcard, D., Carvalho, G., Chirico, M., De Caceres, M., Durand, S., Evangelista, H. B. A., FitzJohn, R., Friendly, M., Furneaux, B., Hannigan, G., Hill, M. O., Lahti, L., McGlinn, D., Ouellette, M., Cunha, E. R., Smith, T., Stier, A., Ter Braak,

C. J. F., and Weedon J. (2022). *vegan: Community Ecology Package*. In R package version 2.6-2. https://CRAN.R-project.org/package=vegan

Oliphant, K., & Allen-Vercoe, E. (2019). Macronutrient metabolism by the human gut microbiome: major fermentation by-products and their impact on host health. *Microbiome*, *7*(1), 91. https://doi.org/10.1186/s40168-019-0704-8

Parcon, P. A., Balasubramaniam, M., Ayyadevara, S., Jones, R. A., Liu, L., Shmookler Reis, R. J., Barger, S. W., Mrak, R. E., & Griffin, W. S. T. (2018). Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs. *Alzheimers Dement*, *14*(2), 230-242. https://doi.org/10.1016/j.jalz.2017.07.754

Parker, B. J., Wearsch, P. A., Veloo, A. C. M., & Rodriguez-Palacios, A. (2020). The Genus Alistipes: Gut Bacteria With Emerging Implications to Inflammation, Cancer, and Mental Health. *Front Immunol*, *11*, 906. https://doi.org/10.3389/fimmu.2020.00906

Peet, R. K. (1974). The Measurement of Species Diversity. *Annual Review of Ecology and Systematics*, *5*(1), 285-307. https://doi.org/10.1146/annurev.es.05.110174.001441

Poillet-Perez, L., Xie, X., Zhan, L., Yang, Y., Sharp, D. W., Hu, Z. S., Su, X., Maganti, A., Jiang, C., Lu, W., Zheng, H., Bosenberg, M. W., Mehnert, J. M., Guo, J. Y., Lattime, E., Rabinowitz, J. D., & White, E. (2018). Autophagy maintains tumour growth through circulating arginine. *Nature*, *563*(7732), 569-573. https://doi.org/10.1038/s41586-018-0697-7

Pugin, B., Barcik, W., Westermann, P., Heider, A., Wawrzyniak, M., Hellings, P., Akdis, C. A., & O'Mahony, L. (2017). A wide diversity of bacteria from the human gut produces and degrades biogenic amines. *Microb Ecol Health Dis*, *28*(1), 1353881. https://doi.org/10.1080/16512235.2017.1353881

Rodriguez-Palacios, A., Conger, M., Hopperton, A., Ezeji, J. C., Erkkila, H. L., Fiocchi, C., & Cominelli, F. (2019). 25 IDENTIFICATION OF PATHOGENIC BACTERIA IN SEVERE CROHN'S DISEASE. *Inflammatory Bowel Diseases*, *25*(Supplement_1), S70-S70. https://doi.org/10.1093/ibd/izy393.175

Rogers, G. B., Keating, D. J., Young, R. L., Wong, M. L., Licinio, J., & Wesselingh, S. (2016). From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. *Mol Psychiatry*, *21*(6), 738-748. https://doi.org/10.1038/mp.2016.50

Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., Chesselet, M. F., Keshavarzian, A., Shannon, K. M., Krajmalnik-Brown, R., Wittung-Stafshede, P., Knight, R., & Mazmanian, S. K. (2016). Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. *Cell*, *167*(6), 1469-1480 e1412. https://doi.org/10.1016/j.cell.2016.11.018

Sankowski, R., Mader, S., & Valdes-Ferrer, S. I. (2015). Systemic inflammation and the brain: novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. *Front Cell Neurosci*, *9*, 28. https://doi.org/10.3389/fncel.2015.00028

Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016). The Central Nervous System and the Gut Microbiome. *Cell*, *167*(4), 915-932. https://doi.org/10.1016/j.cell.2016.10.027

Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., Rojas, J. C., Gallardo, G., Wang, K., Roh, J., Robinson, G., Finn, M. B., Jiang, H., Sullivan, P. M., Baufeld, C., Wood, M. W., Sutphen, C., McCue, L., Xiong, C., Del-Aguila, J. L., Morris, J. C., Cruchaga, C., Alzheimer's Disease Neuroimaging, I., Fagan, A. M., Miller, B. L., Boxer, A. L., Seeley, W. W., Butovsky, O., Barres, B. A., Paul, S. M., & Holtzman, D. M. (2017). ApoE4 markedly exacerbates

tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature*, *549*(7673), 523-527. https://doi.org/10.1038/nature24016

Shoubridge, A. P., Choo, J. M., Martin, A. M., Keating, D. J., Wong, M. L., Licinio, J., & Rogers, G. B. (2022). The gut microbiome and mental health: advances in research and emerging priorities. *Mol Psychiatry*, *27*(4), 1908-1919. https://doi.org/10.1038/s41380-022-01479-w

Soto, M., Herzog, C., Pacheco, J. A., Fujisaka, S., Bullock, K., Clish, C. B., & Kahn, C. R. (2018). Gut microbiota modulate neurobehavior through changes in brain insulin sensitivity and metabolism. *Mol Psychiatry*, *23*(12), 2287-2301. https://doi.org/10.1038/s41380-018-0086-5

Stadlbauer, V., Engertsberger, L., Komarova, I., Feldbacher, N., Leber, B., Pichler, G., Fink, N., Scarpatetti, M., Schippinger, W., Schmidt, R., & Horvath, A. (2020). Dysbiosis, gut barrier dysfunction and inflammation in dementia: a pilot study. *BMC Geriatr*, *20*(1), 248. https://doi.org/10.1186/s12877-020-01644-2

Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018). Inflammation in CNS neurodegenerative diseases. *Immunology*, *154*(2), 204-219. https://doi.org/10.1111/imm.12922

Strandwitz, P. (2018). Neurotransmitter modulation by the gut microbiota. *Brain Res*, *1693*(Pt B), 128-133. https://doi.org/10.1016/j.brainres.2018.03.015

Sun, M. F., Zhu, Y. L., Zhou, Z. L., Jia, X. B., Xu, Y. D., Yang, Q., Cui, C., & Shen, Y. Q. (2018). Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-alpha signaling pathway. *Brain Behav Immun*, *70*, 48-60. https://doi.org/10.1016/j.bbi.2018.02.005

Suzuki, H., Yamashiro, D., Ogawa, S., Kobayashi, M., Cho, D., Iizuka, A., Tsukamoto-Yasui, M., Takada, M., Isokawa, M., Nagao, K., & Fujiwara, Y. (2020). Intake of Seven Essential Amino Acids Improves Cognitive Function and Psychological and Social Function in Middle-Aged and Older Adults: A Double-Blind, Randomized, Placebo-Controlled Trial. *Front Nutr*, *7*, 586166. https://doi.org/10.3389/fnut.2020.586166

Takahashi, K., Nishida, A., Fujimoto, T., Fujii, M., Shioya, M., Imaeda, H., Inatomi, O., Bamba, S., Sugimoto, M., & Andoh, A. (2016). Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease. *Digestion*, *93*(1), 59-65. https://doi.org/10.1159/000441768

Tsuang, D., Leverenz, J. B., Lopez, O. L., Hamilton, R. L., Bennett, D. A., Schneider, J. A., Buchman, A. S., Larson, E. B., Crane, P. K., Kaye, J. A., Kramer, P., Woltjer, R., Kukull, W., Nelson, P. T., Jicha, G. A., Neltner, J. H., Galasko, D., Masliah, E., Trojanowski, J. Q., Schellenberg, G. D., Yearout, D., Huston, H., Fritts-Penniman, A., Mata, I. F., Wan, J. Y., Edwards, K. L., Montine, T. J., & Zabetian, C. P. (2012). GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. *Neurology*, *79*(19), 1944-1950. https://doi.org/10.1212/WNL.0b013e3182735e9a

Ulrich, J. D., Ulland, T. K., Mahan, T. E., Nystrom, S., Nilsson, K. P., Song, W. M., Zhou, Y., Reinartz, M., Choi, S., Jiang, H., Stewart, F. R., Anderson, E., Wang, Y., Colonna, M., & Holtzman, D. M. (2018). ApoE facilitates the microglial response to amyloid plaque pathology. *J Exp Med*, *215*(4), 1047-1058. https://doi.org/10.1084/jem.20171265

Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y., Schiweck, C., Kurilshikov, A., Joossens, M., Wijmenga, C., Claes, S., Van Oudenhove, L., Zhernakova, A., Vieira-Silva, S., & Raes, J. (2019). The neuroactive potential of the human gut microbiota in quality of life and depression. *Nat Microbiol*, *4*(4), 623-632. https://doi.org/10.1038/s41564-018-0337-x

van Soest, A. P. M., Hermes, G. D. A., Berendsen, A. A. M., van de Rest, O., Zoetendal, E. G., Fuentes, S., Santoro, A., Franceschi, C., de Groot, L., & de Vos, W. M. (2020). Associations between Pro- and Anti-Inflammatory Gastro-Intestinal Microbiota, Diet, and Cognitive Functioning in Dutch Healthy Older Adults: The NU-AGE Study. *Nutrients*, *12*(11). https://doi.org/10.3390/nu12113471

Verdi, S., Jackson, M. A., Beaumont, M., Bowyer, R. C. E., Bell, J. T., Spector, T. D., & Steves, C. J. (2018). An Investigation Into Physical Frailty as a Link Between the Gut Microbiome and Cognitive Health. *Front Aging Neurosci*, *10*, 398. https://doi.org/10.3389/fnagi.2018.00398

Vogt, N. M., Kerby, R. L., Dill-McFarland, K. A., Harding, S. J., Merluzzi, A. P., Johnson, S. C., Carlsson, C. M., Asthana, S., Zetterberg, H., Blennow, K., Bendlin, B. B., & Rey, F. E. (2017). Gut microbiome alterations in Alzheimer's disease. *Sci Rep*, *7*(1), 13537. https://doi.org/10.1038/s41598-017-13601-y

Wang, T., Cai, G., Qiu, Y., Fei, N., Zhang, M., Pang, X., Jia, W., Cai, S., & Zhao, L. (2012). Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. *ISME J*, *6*(2), 320-329. https://doi.org/10.1038/ismej.2011.109

Wasser, C. I., Mercieca, E. C., Kong, G., Hannan, A. J., McKeown, S. J., Glikmann-Johnston, Y., & Stout, J. C. (2020). Gut dysbiosis in Huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes. *Brain Commun*, *2*(2), fcaa110. https://doi.org/10.1093/braincomms/fcaa110

Weaver, G. A., Krause, J. A., Miller, T. L., & Wolin, M. J. (1986). Incidence of methanogenic bacteria in a sigmoidoscopy population: an association of methanogenic bacteria and diverticulosis. *Gut*, *27*(6), 698-704. https://doi.org/10.1136/gut.27.6.698

Wu, L., Zeng, T., Zinellu, A., Rubino, S., Kelvin, D. J., & Carru, C. (2019). A Cross-Sectional Study of Compositional and Functional Profiles of Gut Microbiota in Sardinian Centenarians. *mSystems*, *4*(4). https://doi.org/10.1128/mSystems.00325-19

Yano, J. M., Yu, K., Donaldson, G. P., Shastri, G. G., Ann, P., Ma, L., Nagler, C. R., Ismagilov, R. F., Mazmanian, S. K., & Hsiao, E. Y. (2015). Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. *Cell*, *161*(2), 264-276. https://doi.org/10.1016/j.cell.2015.02.047

Ye, B. S., Seo, S. W., Kim, J. H., Kim, G. H., Cho, H., Noh, Y., Kim, H. J., Yoon, C. W., Woo, S. Y., Kim, S. H., Park, H. K., Kim, S. T., Choe, Y. S., Lee, K. H., Kim, J. S., Oh, S. J., Kim, C., Weiner, M., Lee, J. H., & Na, D. L. (2015). Effects of amyloid and vascular markers on cognitive decline in subcortical vascular dementia. *Neurology*, *85*(19), 1687-1693. https://doi.org/10.1212/WNL.0000000000002097

Ye, L., Bae, M., Cassilly, C. D., Jabba, S. V., Thorpe, D. W., Martin, A. M., Lu, H. Y., Wang, J., Thompson, J. D., Lickwar, C. R., Poss, K. D., Keating, D. J., Jordt, S. E., Clardy, J., Liddle, R. A., & Rawls, J. F. (2021). Enteroendocrine cells sense bacterial tryptophan catabolites to activate enteric and vagal neuronal pathways. *Cell Host Microbe*, *29*(2), 179-196 e179. https://doi.org/10.1016/j.chom.2020.11.011

Figures and Tables

Demographic	Mild (n=46)	Moderate (n=58)	Severe (n=55)	Total (n=159)
Age (years): Median (IQR)	87.5 (81.3;93.6)	90.3 (83.7;95.0)	87.9 (82.0;93.0)	88.7(82.1; 93.5)
Sex: n (%) Female Male	27 (58.7) 19 (41.3)	42 (72.4) 16 (27.6)	40 (72.7) 15 (27.3)	109 (68.6) 50 (31.4)
PAS-CIS: Median (IQR)	6.6 (5.0;8.0)	11.0 (11.0;12.8)	18.0 (17.0;18.8)	10.8 (7.0;18.0)
Time between CI assessment and stool collection (days): Median (IQR)	345.5 (148.5,654.5)	421.5 (182.3,734.3)	487.0 (252.0,909.0)	437.0 (185.0,741.0)
Time since entry to facility (days): Median (IQR)	500 (253.0,947.5)	704 (299.0,983.0)	962 (502.0,1198.0)	681 (360.0,1015.0)
Dementia diagnosis: % (n)[#]	8.7 (4)	56.9 (33)	96.4 (53)	56.6 (90)
Memory Support Unit^: n (%)	0 (0.0)	4 (6.9)	19 (34.5)	23 (14.5)
Meal texture: n (%) Regular Soft/smooth	38 (82.6) 8 (17.4)	44 (75.9) 14 (24.1)	30 (54.5) 25 (45.5)	112 (70.4) 47 (29.6)
Liquid texture: n (%) Normal/thin Thick	42 (91.3) 4 (8.7)	54 (93.1) 4 (6.9)	49 (89.1) 6 (10.9)	145 (91.2) 14 (8.8)
Antibiotics (at least 2 supplied[*]): n (%)	10 (21.7)	7 (12.1)	5 (9.1)	22 (13.8)
Proton pump inhibitors (at least 2 supplied[*]): n (%)	23 (50.0)	23 (39.7)	12 (21.8)	58 (36.5)
Opioids (at least 2 supplied[*]): n (%)	8 (17.4)	12 (20.7)	14 (25.5)	34 (21.4)
Laxatives (at least 2 supplied[*]): n (%)	6 (13.0)	6 (10.3)	9 (16.4)	21 (13.2)

Table 1. Study Cohort Characteristics by Severity of Cognitive Impairment.

[#]Extracted from Aged Care Funding Instrument data.

^Memory support units (also known as dementia units/wards, memory care, or special care

units) are secure areas within long-term care facilities specially designed to accommodate

residents with dementia.

[*]Medication use defined as two or more supplies of the same medication within 90 days prior

to stool collection.

Figure 1. Gut microbiome of residents of long-term aged care facilities stratified by cognitive impairment (CI). A) Taxa bar plot of core species (present in >60% of participants).

Species coloured by phyla: Actinomycetota = blues; Bacteroidota = oranges; Bacillota = greens; Pseudomonadota = purples; non-core species (other) = grey. **B**) The frequency of genera detected and their median relative abundances, labelled with core genera. **C**) Non-metric multidimensional scaling plot of Bray-Curtis similarity matrix, grouped by CI severity (mild, n=46; moderate, n=58; severe, n=55), showing significant divergence between CI groups following multivariate analysis (p(perm)=0.0003). **D**) Odds ratio and 95% confidence interval of effect of CI severity on microbiome diversity (taxa richness, Shannon-Wiener diversity, and Pielou's evenness), following multivariate analysis. Multivariate analysis adjusted for time since CI assessment, age, sex, antibiotic use, proton pump inhibitor use, opioid use, laxative use, recorded medical history, meal texture, and liquid texture. ns=not significant; **p<0.01; ***p<0.001 following FDR correction.

	Unadjusted Model			Multivariate-adjusted Model[a]		
Main Test	**Pseudo-F Ratio**	R^2	**p(perm)^**	**Pseudo-F Ratio**	R^2	**p(perm)^**
Cognitive Impairment*	1.9646	0.0246	**0.0002**	1.815	0.0221	**0.0003**
Pairwise Test	t		**p(perm)^**	t		**p(perm)^**
Mild v Moderate	1.0596		0.2583	1.1135		0.1478
Mild v Severe	1.4474		**0.0017**	1.4228		**0.0023**
Moderate v Severe	1.6304		**0.0002**	1.5265		**0.0003**

1038

Table 2. Permutational ANOVA of the gut microbiome by severity of cognitive impairment.

[a]Time since cognitive impairment assessment + age + sex+ antibiotic use + proton pump

inhibitor use + opioid use + laxative use + recorded medication history + meal texture + liquid

texture.

^Permutation p-value generated with a PERMANOVA.

*Degrees of freedom = 2.

1045

Figure 2. Phyla-level differences in the gut microbiome of residents of long-term aged care by cognitive impairment. Odds ratio and 95% confidence interval of effect of cognitive impairment severity on phyla relative abundance. Performed by multivariate analysis, adjusting for time since cognitive impairment assessment, age, sex, antibiotic use, proton pump inhibitor use, opioid use, laxative use, recorded medical history, meal texture, and liquid texture. #Denotes phyla with recently amended names: Actinomycetota (Actinobacteria), Synergistota (Synergistetes), Bacillota (Firmicutes), and Pseudomonadota (Proteobacteria). *p<0.05; ***p<0.001 following FDR correction.

Relation of species to severity of cognitive impairment

Adjusted odds ratio with 95% confidence interval

1055

Figure 3. Species-level differences in the gut microbiome of residents of long-term aged care by cognitive impairment. Odds ratio and 95% confidence interval of effect of cognitive impairment severity on species relative abundance. Performed by multivariate analysis, adjusting for time since cognitive impairment assessment, age, sex, antibiotic use, proton pump inhibitor use, opioid use, laxative use, recorded medical history, meal texture, and liquid texture. $*p<0.05$; $**p<0.01$; $***p<0.001$ following FDR correction.

1062

1063

Figure 4. Specific functional differences in the gut microbiome of residents of long-term

aged care by cognitive impairment. Functional pathways assessed relate to capacity for

production of neurotransmitters, short-chain fatty acids, and amino acids. Odds ratio and 95%

confidence interval of effect of cognitive impairment severity on functional pathway relative

abundance. Performed by multivariate analysis, adjusting for time since cognitive impairment

assessment, age, sex, antibiotic use, proton pump inhibitor use, opioid use, laxative use,

recorded medical history, meal texture, and liquid texture. *p<0.05; **p<0.01; ***p<0.001

following FDR correction.